| Send E-mail to: neamati@usc.edu | |
| Telephone: 323-442-2341 | Fax: 323-442-1390 |
| Office: PSC 304 | Mail Code: 9121 HSC |
Education:
MS 1984 Chemistry - University of Alabama, Huntsville
MS 1990 Medicinal Chemistry - University of Houston, Texas
PhD 1995 Biomedical Sciences - University of Texas, GSBS, Houston
Postdoctoral Research Fellowship:
1995-1999 National Cancer Institute, National Institute of Health, Bethesda, Maryland
Started at USC: 2000
Research Topics: Cancer Treatment, Cell Cycle, Growth & Proliferation, Cell Death, Protein Chemistry/Enzymology, Drug Design, Delivery, Pharmacology, Structural Biology
Research Description
The overall goal of my lab is to design and develop novel anticancer and antiviral therapeutics useful for clinical trials. The major emphasize of my lab is to foster a multidisciplinary program in modern techniques for drug discovery. We are especially interested to identify small molecule inhibitors via three-dimensional data base searching and to identify drugs targeting HIV-1 integrase, apoptosis, angiogenesis, cell-cycle regulation and DNA repair pathways. Current projects include target identification and target validation, mechanism of drug action and identification of drug binding sites and microarray technology. We will participate in translational research program with the Norris Comprehensive Cancer Center on campus. Students and postdoctoral fellows interested in drug design and discovery, cellular and molecular pharmacology, medicinal and computational chemistry and molecular modeling are especially encouraged to visit the lab and discuss projects.
Selected Publications
Al-Mawsawi LQ, Al-Safi RI, Neamati N. - Anti-infectives clinical progress of HIV-1 integrase inhibitors. - Expert Opin Emerg Drugs [ 2008 ] Jun;13(2):213-25 . PubMed
Al-Mawsawi LQ, Hombrouck A, Dayam R, Debyser Z, Neamati N. - Four-tiered pi interaction at the dimeric interface of HIV-1 integrase critical for DNA integration and viral infectivity. - Virology [ 2008 ] May 30; . PubMed
Gundla R, Kazemi R, Sanam R, Muttineni R, Sarma JA, Dayam R, Neamati N. - Discovery of Novel Small-Molecule Inhibitors of Human Epidermal Growth Factor Receptor-2: Combined Ligand and Target-Based Approach. - J Med Chem [ 2008 ] May 24; . PubMed
Brzozowski Z, Saczewski F, Slawinski J, Sanchez T, Neamati N. - Synthesis and anti-HIV-1 integrase activities of 3-aroyl-2,3-dihydro-1,1-dioxo-1,4,2-benzodithiazines. - Eur J Med Chem [ 2008 ] Mar 4; . PubMed
Garofalo A, Grande F, Brizzi A, Aiello F, Dayam R, Neamati N. - Naphthoxazepine inhibitors of HIV-1 integrase: synthesis and biological evaluation. - ChemMedChem [ 2008 ] Jun;3(6):986-90 . PubMed
Cao Q, Li ZB, Chen K, Wu Z, He L, Neamati N, Chen X. - Evaluation of biodistribution and anti-tumor effect of a dimeric RGD peptide-paclitaxel conjugate in mice with breast cancer. - Eur J Nucl Med Mol Imaging [ 2008 ] Mar 29; . PubMed
Al-Mawsawi LQ, Christ F, Dayam R, Debyser Z, Neamati N. - Inhibitory profile of a LEDGF/p75 peptide against HIV-1 integrase: insight into integrase-DNA complex formation and catalysis. - FEBS Lett [ 2008 ] Apr 30;582(10):1425-30 . PubMed
Grande F, Garofalo A, Neamati N. - Small molecules anti-HIV therapeutics targeting CXCR4. - Curr Pharm Des [ 2008 ] 14(4):385-404 . PubMed
Dayam R, Al-Mawsawi LQ, Zawahir Z, Witvrouw M, Debyser Z, Neamati N. - Quinolone 3-carboxylic acid pharmacophore: design of second generation HIV-1 integrase inhibitors. - J Med Chem [ 2008 ] Mar 13;51(5):1136-44 . PubMed
Dayam R, Gundla R, Al-Mawsawi LQ, Neamati N. - HIV-1 integrase inhibitors: 2005-2006 update. - Med Res Rev [ 2008 ] Jan;28(1):118-54 . PubMed
